Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fraser

Showing results (521-530 of 598) with videos related to

Pageof 60
Sort By:
The Lancet. Oncology|March 3, 2007
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling studyYun Gong, Kai Yan, Feng Lin, et al.
Neurosurgery|November 4, 2015
Comparing Preoperative With Postoperative Stereotactic Radiosurgery for Resectable Brain Metastases: A Multi-institutional AnalysisKirtesh R Patel, Stuart H Burri, Anthony L Asher, et al.
European Journal of Radiology|April 22, 2019
Imaging features of triple-negative breast cancers according to androgen receptor statusRosalind P Candelaria, Beatriz E Adrada, Wei Wei, et al.
NPJ Breast Cancer|May 27, 2024
Targeting neddylation and sumoylation in chemoresistant triple negative breast cancerReid T Powell, Amanda L Rinkenbaugh, Lei Guo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer SubtypeW Fraser Symmans, Caimiao Wei, Rebekah Gould, et al.
American Journal of Public Health|October 17, 2014
Confronting death from drug self-intoxication (DDSI): prevention through a better definitionIan R H Rockett, Gordon S Smith, Eric D Caine, et al.
European Journal of Radiology|August 11, 2020
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patientsRosalind P Candelaria, Beatriz E Adrada, Kenneth Hess, et al.
The Lancet. Oncology|March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialSibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Breast Cancer Research and Treatment|April 28, 2012
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersLibero Santarpia, Yuan Qi, Katherine Stemke-Hale, et al.
Xenotransplantation|August 19, 2014
Increased transfusion-free survival following auxiliary pig liver xenotransplantationHeidi Yeh, Zurab Machaidze, Isaac Wamala, et al.
Pageof 60

Showing results (521-530 of 598) with videos related to

Sort By:
Pageof 60
The Lancet. Oncology|March 3, 2007
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling studyYun Gong, Kai Yan, Feng Lin, et al.
Neurosurgery|November 4, 2015
Comparing Preoperative With Postoperative Stereotactic Radiosurgery for Resectable Brain Metastases: A Multi-institutional AnalysisKirtesh R Patel, Stuart H Burri, Anthony L Asher, et al.
European Journal of Radiology|April 22, 2019
Imaging features of triple-negative breast cancers according to androgen receptor statusRosalind P Candelaria, Beatriz E Adrada, Wei Wei, et al.
NPJ Breast Cancer|May 27, 2024
Targeting neddylation and sumoylation in chemoresistant triple negative breast cancerReid T Powell, Amanda L Rinkenbaugh, Lei Guo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer SubtypeW Fraser Symmans, Caimiao Wei, Rebekah Gould, et al.
American Journal of Public Health|October 17, 2014
Confronting death from drug self-intoxication (DDSI): prevention through a better definitionIan R H Rockett, Gordon S Smith, Eric D Caine, et al.
European Journal of Radiology|August 11, 2020
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patientsRosalind P Candelaria, Beatriz E Adrada, Kenneth Hess, et al.
The Lancet. Oncology|March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialSibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Breast Cancer Research and Treatment|April 28, 2012
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersLibero Santarpia, Yuan Qi, Katherine Stemke-Hale, et al.
Xenotransplantation|August 19, 2014
Increased transfusion-free survival following auxiliary pig liver xenotransplantationHeidi Yeh, Zurab Machaidze, Isaac Wamala, et al.
Pageof 60